Ultrapotent COVID-19 Vaccine Candidate Designed via Computer

An innovative nanoparticle vaccine candidate for the pandemic coronavirus produces virus-neutralizing antibodies in mice at levels ten-times greater than is seen in people who have recovered from COVID-19 infections. Designed by scientists at the University of Washington School of Medicine in Seattle, the vaccine candidate has been transferred to two companies for clinical development.

Compared to vaccination with the soluble SARS-CoV-2 Spike protein, which is what many leading COVID-19 vaccine candidates are based on, the new nanoparticle vaccine produced ten times more neutralizing antibodies in mice, even at a six-fold lower vaccine dose. The data also show a strong B-cell response after immunization, which can be critical for immune memory and a durable vaccine effect. When administered to a single nonhuman primate, the nanoparticle vaccine produced neutralizing antibodies targeting multiple different sites on the Spike protein. Researchers say this may ensure protection against mutated strains of the virus, should they arise. The Spike protein is part of the coronavirus infectivity machinery.

The findings are published in Cell. The lead authors of this paper are Alexandra Walls, a research scientist in the laboratory of David Veesler, who is an associate professor of biochemistry at the UW School of Medicine; and Brooke Fiala, a research scientist in the laboratory of Neil King, who is an assistant professor of biochemistry at the UW School of Medicine.

The vaccine candidate was developed using structure-based vaccine design techniques invented at UW Medicine. It is a self-assembling protein nanoparticle that displays 60 copies of the SARS-CoV-2 Spike protein's receptor-binding domain in a highly immunogenic array. The molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response.

"We hope that our nanoparticle platform may help fight this pandemic that is causing so much damage to our world," said King, inventor of the computational vaccine design technology at the Institute for Protein Design at UW Medicine. "The potency, stability, and manufacturability of this vaccine candidate differentiate it from many others under investigation."

Hundreds of candidate vaccines for COVID-19 are in development around the world. Many require large doses, complex manufacturing, and cold-chain shipping and storage. An ultrapotent vaccine that is safe, effective at low doses, simple to produce and stable outside of a freezer could enable vaccination against COVID-19 on a global scale.

"I am delighted that our studies of antibody responses to coronaviruses led to the design of this promising vaccine candidate," said Veesler, who spearheaded the concept of a multivalent receptor-binding domain-based vaccine.

Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraf, JC, Ogohara C, Palser A, Chalk S, Lee E-C, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon III KH, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP.
Elicitation of potent neutralizing antibody responsesby designed protein nanoparticle vaccines for SARS-CoV-2.
Cell, 2020, doi: https://doi.org/10.1016/j.cell.2020.10.043

Most Popular Now

Hull University Teaching Hospitals NHS T…

Hull University Teaching Hospitals NHS Trust has deployed DXC Technology's (NYSE:DXC) cloud-based Clinical Aide mobile application, which both improves secure access to electronic patient medical records and increases patient and...

Central Hospital in Finland Automates Sy…

This November Central Ostrobothnia Central Hospital in Finland has started symptom tracking and remote monitoring of corona virus-infected patients with the Buddy Healthcare mobile application and clinical monitoring platform. The...

Interactive virtual reality emerges as a…

Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus - and enable researchers to share models and collaborate in...

DMEA Newcomer Award: The Search is on fo…

13 - 15 April 2021, Berlin, Germany. More efficient, digital and patient-friendly! Tomorrow's healthcare system promises great things. And to ensure this becomes reality a fresh impetus and creative ideas are...

App to Help NHS Prevent Deadly Hospital …

Compass app to help NHS trusts prevent hospital-acquired acute kidney injury and pneumonia - both of which cause harm to COVID-19 patients and can be fatal. Hospitals could alleviate pressure...

Leeds Deploys Imaging Tech for Advanced …

A multi-million pound initiative that is digitising, connecting and applying artificial intelligence to NHS pathology services in the North of England has taken an important step, after Leeds Teaching Hospitals...

Survey of COVID-19 Research Provides Fre…

Researchers at Karolinska Institutet in Sweden have explored all COVID-19 research published during the initial phase of the pandemic. The results, which were achieved by using a machine learning-based approach...

COVID-19 High Performance Computing Cons…

The COVID-19 High Performance Computing (HPC) Consortium, a unique public-private effort to make supercomputing power available to researchers working on projects related to COVID-19, announced that it has entered into...

Computer Vision App Allows Easier Monito…

A computer vision technology developed by University of Cambridge engineers has now been developed into a free mobile phone app for regular monitoring of glucose levels in people with diabetes. The...

Bayer Initiates New G4A Digital Health P…

Bayer will support five new startup companies as part of the company's G4A Digital Health Partnerships Program. Focus will be on fostering the development of a digital health ecosystem, while...

Leading Pathology Laboratories Deploy Te…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced leading pathology laboratories across North America, Europe, and Asia have implemented full digitization for their histology...